- IR News
- News Releases
-
- Oct. 03, 2022 (PDF/601KB)Corporate
- Sumitomo Pharma and Sumitovant Biopharma Announce Offer to Acquire Outstanding Shares of Myovant Sciences
-
- Sep. 30, 2022 (PDF/407KB)Licensing
- Sumitomo Pharma and MELTIN Enter into Marketing Alliance for MELTz Hand Rehabilitation System and Launch It
-
- Sep. 29, 2022 (PDF/160KB)R&D
- Joint Research between The Kitasato Institute and Sumitomo Pharma: Drug Combination of Meropenem and KSP-1007 for Treatment of Carbapenem- Resistant Bacteria Infections Designated as Qualified Infectious Disease Product (QIDP)/Fast Track
-
- Sep. 27, 2022 (PDF/183KB)Corporate
- Appeal of Inter Partes Review (IPR) USPTO Decision on the Method of Use Patent for LATUDA
-
- Sep. 13, 2022Others
- Posted Integrated Report 2022
-
- Oct. 03, 2022 (PDF/601KB)Corporate
- Sumitomo Pharma and Sumitovant Biopharma Announce Offer to Acquire Outstanding Shares of Myovant Sciences
-
- Sep. 30, 2022 (PDF/407KB)Licensing
- Sumitomo Pharma and MELTIN Enter into Marketing Alliance for MELTz Hand Rehabilitation System and Launch It
-
- Sep. 29, 2022 (PDF/160KB)R&D
- Joint Research between The Kitasato Institute and Sumitomo Pharma: Drug Combination of Meropenem and KSP-1007 for Treatment of Carbapenem- Resistant Bacteria Infections Designated as Qualified Infectious Disease Product (QIDP)/Fast Track
-
- Sep. 27, 2022 (PDF/183KB)Corporate
- Appeal of Inter Partes Review (IPR) USPTO Decision on the Method of Use Patent for LATUDA
IR Calendar
-
- Oct. 31, 2022
- 2nd Quarter of FY2022 financial results announcement
(planned, 3:30 p.m. )
-
- Nov. 01, 2022
- Analysts meeting of 2nd
Quarter financial results FY2022
-
Recommended Information Rankings
